Avalon Moonen

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND In Australia, government-subsidised treatment of pulmonary arterial hypertension (PAH) is limited to monotherapy. Recent international guidelines advocate that initial combination therapy be considered for all symptomatic PAH patients. AIM To characterise 'real-life' outcomes in PAH patients initiated on monotherapy. METHODS We performed a(More)
  • 1